바이러스 벡터 및 플라스미드 DNA 제조 시장 : 벡터 유형별, 워크플로우별, 질병별, 용도별, 최종 사용자별, 국가별, 지역별 산업 분석, 시장 규모, 시장 점유율 및 예측(2024-2032년)

REPORT HIGHLIGHT

Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,673.98 Million in 2023, expanding at a CAGR of 19.61% from 2024 to 2032.

The Viral Vector and Plasmid DNA Manufacturing sector represents a vital segment within the biopharmaceutical industry, dedicated to producing viral vectors and plasmid DNA for gene therapy and vaccine development purposes. Viral vectors are genetically engineered viruses used to transport therapeutic genes into target cells, while plasmid DNA serves as a critical component in gene therapy and DNA vaccine production. This market significantly contributes to advancing medical treatments by facilitating the development of innovative therapies for a broad spectrum of genetic disorders, infectious diseases, and cancers. Given the rapid progress in biotechnology and the increasing investment in gene therapy research, the demand for viral vectors and plasmid DNA manufacturing continues to steadily rise. This growth is fueled by factors such as the increasing prevalence of genetic diseases, the expanding pipeline of gene therapy candidates, and the growing adoption of personalized medicine approaches.

Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics

Advancements in gene therapy to propel market demand

The primary drivers of the market include advancements in gene therapy, as the development of new gene therapies heavily relies on high-quality viral vectors and plasmid DNA. Moreover, enhancements in manufacturing processes have enabled more efficient production of viral vectors and plasmid DNA at larger scales, leading to cost reductions and improved overall quality. With increased investments in the cell and gene therapy research space, there is significant demand for viral vectors in the market. Consequently, various organizations are providing funds to accelerate developments in manufacturing processes for viral vectors. For instance, in September 2019, Next Generation Manufacturing Canada granted USD 1.89 million to a consortium led by iVexSol Canada for the development of an advanced manufacturing process for lentiviral vectors. iVexSol Canada, a vector manufacturing company, has collaborated with several entities to develop an advanced LVV manufacturing platform.

Viral Vector and Plasmid DNA Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.81% over the forecast period (2024-2032)

Based on Vector Type segmentation, adeno-associated virus was predicted to show maximum market share in the year 2023

Based on Workflow segmentation, downstream processing was the leading type in 2023

Based on Disease segmentation, Cancer was the leading type in 2023

Based on end user segmentation, research institute was the leading type in 2023

Based on Application segmentation, Antisense & RNAi Therapy was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Viral Vector and Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented on the basis of Vector Type, Workflow, Disease, Application, End User and Region.

The market is divided into six categories based on vector type: Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids and Others. In terms of vector type, the adeno-associated virus (AAV) segment led the market with the largest revenue share in 2023. AAVs are in high demand, with their utilization in clinical trials increasing rapidly due to their precision in delivering genes to the region of interest. This rising adoption is attributed to clinical trials related to the development of orthopedic and ocular gene therapies demonstrating increased efficiency and efficacy. An article published in Springer in August 2022 stated that AAV-mediated gene therapy could prevent acquired hearing loss, further highlighting the expanding applications of AAV across various therapeutic areas.

The market is divided into two categories based on Workflow: Upstream Manufacturing and Downstream Manufacturing. Based on the workflow, the downstream processing segment dominated the market in 2023 with the largest revenue share, owing to highly complex procedures involved in polishing and purifying clinical-grade final products. With the growing demand for clinical-grade viral vectors, manufacturers are actively engaged in developing novel, cost-effective downstream processes to address challenges associated with conventional lab-scale vector manufacturing. This approach is expected to support market growth, as seen in examples such as combining fed-batch fermentation techniques and genetically optimized cell systems with conventional and novel purification technologies.

Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Viral Vector and Plasmid DNA Manufacturing Market- Competitive Landscape:

In the dynamic landscape of the Viral Vector and Plasmid DNA Manufacturing market, companies implement diverse strategies to uphold competitiveness and address the evolving demands of the biopharmaceutical industry. Collaboration and strategic partnerships play a crucial role in driving innovation, expanding capabilities, and accessing complementary expertise and resources. Companies frequently establish strategic alliances with biopharmaceutical firms, academic institutions, and contract development and manufacturing organizations (CDMOs) to co-develop gene therapy products, exchange research insights, and utilize manufacturing infrastructure. Moreover, investments in research and development (R&D) are essential for advancing manufacturing technologies, enhancing process efficiency, and improving product quality and scalability. Continuous innovation in upstream and downstream processing techniques, purification methods, and analytical technologies is vital for optimizing viral vector and plasmid DNA production processes. Additionally, ensuring regulatory compliance and adhering to Good Manufacturing Practices (GMP) standards are imperative for maintaining product quality, safety, and efficacy throughout the manufacturing lifecycle.

Recent Developments:

In October 2023, AGC Biologics revealed plans for the expansion of their plasmid DNA (pDNA) manufacturing facility located in Germany. This strategic move is anticipated to enable the company to decrease manufacturing time.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Merck KGaA

Lonza

FUJIFILM Diosynth Biotechnologies

Thermo Fisher Scientific

Cobra Biologics

Catalent Inc.

Wuxi Biologics

Takara Bio Inc.

Waisman Biomanufacturing

Genezen laboratories

Batavia Biosciences

Miltenyi Biotec GmbH

SIRION Biotech GmbH

Virovek Incorporation

Others

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Plasmids
• Others

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2019 - 2032

• Upstream Manufacturing
• Downstream Manufacturing

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1.Viral Vector and Plasmid DNA Manufacturing Market Overview

• 1.1.Study Scope
• 1.2.Market Estimation Years

2.Executive Summary

• 2.1.Market Snippet
  • 2.1.1.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Vector Type
  • 2.1.2.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Workflow
  • 2.1.3.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Disease
  • 2.1.4.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Application
  • 2.1.5.Viral Vector and Plasmid DNA Manufacturing Market Snippet by End User
  • 2.1.6.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Country
  • 2.1.7.Viral Vector and Plasmid DNA Manufacturing Market Snippet by Region
• 2.2.Competitive Insights

3.Viral Vector and Plasmid DNA Manufacturing Key Market Trends

• 3.1.Viral Vector and Plasmid DNA Manufacturing Market Drivers
  • 3.1.1.Impact Analysis of Market Drivers
• 3.2.Viral Vector and Plasmid DNA Manufacturing Market Restraints
  • 3.2.1.Impact Analysis of Market Restraints
• 3.3.Viral Vector and Plasmid DNA Manufacturing Market Opportunities
• 3.4.Viral Vector and Plasmid DNA Manufacturing Market Future Trends

4.Viral Vector and Plasmid DNA Manufacturing Industry Study

• 4.1.PEST Analysis
• 4.2.Porter's Five Forces Analysis
• 4.3.Growth Prospect Mapping
• 4.4.Regulatory Framework Analysis

5.Viral Vector and Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis

• 5.1.Pre-COVID-19 Impact Analysis
• 5.2.Post-COVID-19 Impact Analysis
  • 5.2.1.Top Performing Segments
  • 5.2.2.Marginal Growth Segments
  • 5.2.3.Top Looser Segments
  • 5.2.4.Marginal Loss Segments

6.Viral Vector and Plasmid DNA Manufacturing Market Landscape

• 6.1.Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, 2023
• 6.2.Breakdown Data, by Key Manufacturer
  • 6.2.1.Established Players' Analysis
  • 6.2.2.Emerging Players' Analysis

7.Viral Vector and Plasmid DNA Manufacturing Market - By Vector Type

• 7.1.Overview
  • 7.1.1.Segment Share Analysis, By Vector Type, 2023 & 2032 (%)
  • 7.1.2.Adenovirus
  • 7.1.3.Retrovirus
  • 7.1.4.Adeno-Associated Virus (AAV)
  • 7.1.5.Lentivirus
  • 7.1.6.Plasmids
  • 7.1.7.Others

8.Viral Vector and Plasmid DNA Manufacturing Market - By Workflow

• 8.1.Overview
  • 8.1.1.Segment Share Analysis, By Workflow, 2023 & 2032 (%)
  • 8.1.2.Upstream Manufacturing
  • 8.1.3.Downstream Manufacturing

9.Viral Vector and Plasmid DNA Manufacturing Market - By Disease

• 9.1.Overview
  • 9.1.1.Segment Share Analysis, By Disease, 2023 & 2032 (%)
  • 9.1.2.Cancer
  • 9.1.3.Genetic Disorders
  • 9.1.4.Infectious Diseases
  • 9.1.5.Others

10.Viral Vector and Plasmid DNA Manufacturing Market - By Application

• 10.1.Overview
  • 10.1.1.Segment Share Analysis, By Application, 2023 & 2032 (%)
  • 10.1.2.Antisense & RNAi Therapy
  • 10.1.3.Gene Therapy
  • 10.1.4.Cell Therapy
  • 10.1.5.Vaccinology
  • 10.1.6.Research Applications

11.Viral Vector and Plasmid DNA Manufacturing Market - By End User

• 11.1.Overview
  • 11.1.1.Segment Share Analysis, By End User, 2023 & 2032 (%)
  • 11.1.2.Pharmaceutical and Biopharmaceutical Companies
  • 11.1.3.Research Institutes

12.Viral Vector and Plasmid DNA Manufacturing Market- By Geography

• 12.1.Introduction
  • 12.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 12.2.North America
  • 12.2.1.Overview
  • 12.2.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in North America
  • 12.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.2.4.North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  • 12.2.5.North America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  • 12.2.6.North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 12.2.7.North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.2.8.North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.2.9.U.S.
    • 12.2.9.1.Overview
    • 12.2.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.2.9.3.U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.2.9.4.U.S. Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.2.9.5.U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.2.9.6.U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.9.7.U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.2.10.Canada
    • 12.2.10.1.Overview
    • 12.2.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.2.10.3.Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.2.10.4.Canada Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.2.10.5.Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.2.10.6.Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.10.7.Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.3.Europe
  • 12.3.1.Overview
  • 12.3.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Europe
  • 12.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.3.4.Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  • 12.3.5.Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  • 12.3.6.Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 12.3.7.Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.3.8.Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.9.Germany
    • 12.3.9.1.Overview
    • 12.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.9.3.Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.9.4.Germany Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.9.5.Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.9.6.Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.9.7.Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.10.Italy
    • 12.3.10.1.Overview
    • 12.3.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.10.3.Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.10.4.Italy Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.10.5.Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.10.6.Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.10.7.Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.11.United Kingdom
    • 12.3.11.1.Overview
    • 12.3.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.11.3.United Kingdom Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.11.4.United Kingdom Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.11.5.United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.11.6.United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.11.7.United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.12.France
    • 12.3.12.1.Overview
    • 12.3.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.12.3.France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.12.4.France Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.12.5.France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.12.6.France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.12.7.France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.13.Russia
    • 12.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.13.2.Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.13.3.Russia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.13.4.Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.13.5.Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.13.6.Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.14.Netherlands
    • 12.3.14.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.14.2.Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.14.3.Netherlands Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.14.4.Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.14.5.Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.14.6.Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.15.Sweden
    • 12.3.15.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.15.2.Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.15.3.Sweden Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.15.4.Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.15.5.Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.15.6.Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.16.Poland
    • 12.3.16.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.16.2.Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.16.3.Poland Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.16.4.Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.16.5.Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.16.6.Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3.17.Rest of Europe
    • 12.3.17.1.Overview
    • 12.3.17.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.3.17.3.Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.17.4.Rest of the Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.17.5.Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.3.17.6.Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.17.7.Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.4.Asia Pacific (APAC)
  • 12.4.1.Overview
  • 12.4.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
  • 12.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.4.4.Asia Pacific Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  • 12.4.5.Asia Pacific Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  • 12.4.6.Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 12.4.7.Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.4.8.Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.9.India
    • 12.4.9.1.Overview
    • 12.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.9.3.India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.9.4.India Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.9.5.India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.9.6.India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.9.7.India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.10.China
    • 12.4.10.1.Overview
    • 12.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.10.3.China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.10.4.China Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.10.5.China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.10.6.China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.10.7.China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.11.Japan
    • 12.4.11.1.Overview
    • 12.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.11.3.Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.11.4.Japan Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.11.5.Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.11.6.Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.11.7.Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.12.South Korea
    • 12.4.12.1.Overview
    • 12.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.12.3.South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.12.4.South Korea Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.12.5.South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.12.6.South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.12.7.South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.13.Australia
    • 12.4.13.1.Overview
    • 12.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.13.3.Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.13.4.Australia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.13.5.Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.13.6.Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.13.7.Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.14.Thailand
    • 12.4.14.1.Overview
    • 12.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.14.3.Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.14.4.Thailand Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.14.5.Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.14.6.Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.14.7.Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.15.Indonesia
    • 12.4.15.1.Overview
    • 12.4.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.15.3.Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.15.4.Indonesia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.15.5.Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.15.6.Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.15.7.Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.16.Philippines
    • 12.4.16.1.Overview
    • 12.4.16.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.16.3.Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.16.4.Philippines Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.16.5.Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.16.6.Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.16.7.Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4.17.Rest of APAC
    • 12.4.17.1.Overview
    • 12.4.17.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.4.17.3.Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.17.4.Rest of APAC Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.17.5.Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.4.17.6.Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.17.7.Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.5.Latin America
  • 12.5.1.Overview
  • 12.5.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Latin America
  • 12.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.5.4.Latin America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  • 12.5.5.Latin America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  • 12.5.6.Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 12.5.7.Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.5.8.Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.9.Brazil
    • 12.5.9.1.Overview
    • 12.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.9.3.Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.9.4.Brazil Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.9.5.Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.5.9.6.Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.9.7.Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.10.Mexico
    • 12.5.10.1.Overview
    • 12.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.10.3.Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.10.4.Mexico Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.10.5.Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.5.10.6.Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.10.7.Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.11.Argentina
    • 12.5.11.1.Overview
    • 12.5.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.11.3.Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.11.4.Argentina Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.11.5.Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.5.11.6.Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.11.7.Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.12.Colombia
    • 12.5.12.1.Overview
    • 12.5.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.12.3.Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.12.4.Colombia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.12.5.Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.5.12.6.Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.12.7.Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5.13.Rest of LATAM
    • 12.5.13.1.Overview
    • 12.5.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.5.13.3.Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.13.4.Rest of LATAM Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.13.5.Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.5.13.6.Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.13.7.Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 12.6.Middle East and Africa
  • 12.6.1.Overview
  • 12.6.2.Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
  • 12.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 12.6.4.Middle East and Africa Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
  • 12.6.5.Middle East and Africa Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
  • 12.6.6.Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 12.6.7.Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.6.8.Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.9.Saudi Arabia
    • 12.6.9.1.Overview
    • 12.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.9.3.Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.9.4.Saudi Arabia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.9.5.Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.9.6.Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.9.7.Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.10.United Arab Emirates
    • 12.6.10.1.Overview
    • 12.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.10.3.United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.10.4.United Arab Emirates Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.10.5.United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.10.6.United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.10.7.United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.11.Israel
    • 12.6.11.1.Overview
    • 12.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.11.3.Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.11.4.Israel Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.11.5.Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.11.6.Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.11.7.Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.12.Turkey
    • 12.6.12.1.Overview
    • 12.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.12.3.Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.12.4.Turkey Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.12.5.Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.12.6.Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.12.7.Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.13.Algeria
    • 12.6.13.1.Overview
    • 12.6.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.13.3.Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.13.4.Algeria Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.13.5.Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.13.6.Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.13.7.Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.14.Egypt
    • 12.6.14.1.Overview
    • 12.6.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.14.3.Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.14.4.Egypt Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.14.5.Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.14.6.Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.14.7.Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6.15.Rest of MEA
    • 12.6.15.1.Overview
    • 12.6.15.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 12.6.15.3.Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.15.4.Rest of MEA Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.15.5.Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 12.6.15.6.Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.15.7.Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13.Key Vendor Analysis- Viral Vector and Plasmid DNA Manufacturing Industry

• 13.1.Competitive Dashboard
• 13.2.Company Profiles
  • 13.2.1.Merck KGaA
  • 13.2.2.Lonza
  • 13.2.3.FUJIFILM Diosynth Biotechnologies
  • 13.2.4.Thermo Fisher Scientific
  • 13.2.5.Cobra Biologics
  • 13.2.6.Catalent Inc.
  • 13.2.7.Wuxi Biologics
  • 13.2.8.Takara Bio Inc.
  • 13.2.9.Waisman Biomanufacturing
  • 13.2.10.Genezen laboratories
  • 13.2.11.Batavia Biosciences
  • 13.2.12.Miltenyi Biotec GmbH
  • 13.2.13.SIRION Biotech GmbH
  • 13.2.14.Virovek Incorporation
  • 13.2.15.Others

14.360 Degree Analyst View

15.Appendix

• 15.1.Research Methodology
• 15.2.References
• 15.3.Abbreviations
• 15.4.Disclaimer
• 15.5.Contact Us